Is fluorescence in-situ hybridization sufficient in patients with myelodysplastic syndromes and insufficient cytogenetic testing?

AbstractChromosome banding analysis (CBA) in myelodysplastic syndromes (MDS) remains the ‘gold standard’ for identification of chromosomal abnormalities, while interphase fluorescence in-situ hybri...